NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

COVID-19 診斷的全球市場:技術、產品、渠道、國家預測、分析數量和到 2025 年的市場規模展望,更新包括 2020 年的表現

COVID-19 Diagnostics. Global C19 Diagnostic Market Forecast by Technology, Product, Channel and Country. Assay Volumes and Market Size Outlook to 2025. Updated to include 2020 Actuals

出版商 Howe Sound Research 商品編碼 1016544
出版日期 內容資訊 英文 342 Pages
商品交期: 最快1-2個工作天內
價格
COVID-19 診斷的全球市場:技術、產品、渠道、國家預測、分析數量和到 2025 年的市場規模展望,更新包括 2020 年的表現 COVID-19 Diagnostics. Global C19 Diagnostic Market Forecast by Technology, Product, Channel and Country. Assay Volumes and Market Size Outlook to 2025. Updated to include 2020 Actuals
出版日期: 2021年06月18日內容資訊: 英文 342 Pages
簡介

本報告調查了全球 COVID-19 診斷市場,按收入、測試數量、技術、產品、渠道、國家和地區、市場預測、市場指南和形勢分析進行了詳細細分,關鍵提供了公司等信息個人資料。

目錄

第 1 章市場指南

  • COVID-19:戰略形勢分析
  • COVID-19:高管指南
  • COVID-19:管理顧問和投資顧問指南

第 2 章市場的介紹和定義

  • 什麼是流行病?
  • 人畜共患病的作用
  • 市場定義
  • 調查方法
  • 流行病的歷史展望
    • 愛滋病毒/愛滋病大流行(2005-2012)
    • 流感大流行(1968 年)
    • 亞洲感冒 (1956-1958)
    • 西班牙流感 (1918)
    • 第六次霍亂大流行(1910-1911)
    • 流感大流行(1889-1890)
    • 黑死病 (1346-1353)

第 3 章大流行概述

  • 什麼是病毒?
    • 病毒還活著嗎?
    • 病毒結構
    • 病毒基因組
    • 病毒變異
  • 冠狀病毒
    • 嚴重急性呼吸系統症候群 (SARS)
    • 中東呼吸症候群 (MERS)
    • COVID-19:SARS CoV2 病毒
  • 流行病診斷
    • 風險管理-激發和傳播
    • Dx 技術-基於核酸
    • Dx Technology-免疫分析
    • 上市時間和準備問題

第 4 章診斷公司簡介

  • Abacus Diagnostica
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Acces Bio
  • Advanced Biological Laboratories
  • Agena Bioscience, Inc.
  • Agilent/Dako
  • Altona Diagnostics
  • Alveo Technologies
  • Anatolia Geneworks
  • Applied BioCode
  • Applied DNA Sciences
  • Assurance Scientific Laboratories
  • Aus Diagnostics
  • Autobio Diagnostics
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • BillionToOne
  • Binx Health
  • Biocartis
  • Biodesix Inc.
  • BioFire Diagnostics (bioMérieux)
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid (Danaher)
  • Chembio
  • Co Diagnostics
  • Color Genomics
  • Cue Health
  • Curetis N.V./Curetis GmbH
  • Diagenode Diagnostics
  • Diasorin S.p.A.
  • Ellume
  • Enzo Life Sciences, Inc.
  • Everywell
  • Fluxergy
  • Fulgent Genetics
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx (Roche)
  • Gold Standard Diagnostics
  • Hologic
  • Illumina
  • Immunexpress
  • Inflammatix
  • Janssen Diagnostics
  • Karius
  • Laboratory Corporation of America
  • Letsgetchecked
  • Lexagene
  • Luminex Corp
  • LumiraDx
  • Mammoth Biosciences
  • Mayo Clinic Laboratories
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech (Thermo Fisher)
  • Mobidiag (Hologic)
  • Nanomix
  • Novacyt
  • Orasure
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Primerdesign (Novacyt)
  • Prominex
  • Qiagen Gmbh
  • QuantuMDx
  • Quest Diagnostics
  • Quidel
  • Randox Toxicology
  • Roche Molecular Diagnostics
  • SD Biosensor
  • Seegene
  • Sherlock Biosciences
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • Thermo Fisher Scientific Inc
  • Veredus Laboratories
  • Vircell
  • Visby Medical
  • YD Diagnostics
  • Zhejiang Orient Gene Biotech

第 5 章 Covid-19 診斷的最新進展

  • 最新動態-重要性和章節使用
    • 發展的重要性
    • 方式的使用方法
  • LetsGetChecked 完成 1.5 億美元融資
  • Novayt 獲得多基因 SARS-CoV-2 測試的 CE 標誌並開始 RUO 變異檢測
  • 雅培預測 COVID-19 檢驗收入將急劇下降
  • Phosphorus Diagnostics 獲得 EUA 用於 DTCC19 測試,樣品收集套件
  • 紐約時報考慮多重檢查
  • Hologic Banking 收購 MDx
  • 對 Cepheid SARS-CoV-2 護理點測試的需求將持續到 2022 年
  • Dia Sorin 收購 Luminex 以擴大 MDx 產品組合併擴大美國業務
  • Lumira Dx 通過 SPAC 發佈
  • Eurofins 測試有助於識別突變
  • 羅氏增加診斷機會的前景
  • 羅氏以 18 億美元收購 GenMark Diagnostics
  • Fulgent Genetics 利用 COVID-19 檢測的優勢促進臨床測序
  • LexaGene 的 Syndrome Panel Platform 允許實驗室定制他們的目標
  • FDA 允許對 DTC 樣品採集試劑盒進行 EUA、兩種分子檢測
  • 家庭傳染病測試開發商 Lucira Health 發佈

第 6 章 COVID-19 全球診斷市場

  • 按國家/地區分列的全球市場概覽
  • 按技術概述的全球市場
  • 按產品概覽劃分的全球市場
  • 按渠道概覽劃分的全球市場

第 7 章全球 COVID-19 診斷市場-按技術

  • PCR
  • PCR 多重
  • 序列
  • 抗體
  • 抗原

第 8 章全球 COVID-19 診斷市場-按產品

  • 設備
  • 試劑和試劑盒
  • 提取
  • 採取

第 9 章全球 COVID-19 診斷市場-按渠道

  • 公眾
  • 醫院
  • 診所
  • 工作場所
  • DTC/OTC
  • 廢水

第 10 章附錄

  • COVID-19 檢測在美國、歐洲和亞洲獲得批准
目錄

OVERVIEW:

A new dynamic market is emerging for Covid - 19 based diagnostics. Testing is moving into physicians' offices and even into the home. Handheld multiplex testers? Home based testing sticks? And what about the Workplace market where safety is paramount? And what happens to the large laboratory capacity that was built up to handle a pandemic now in decline? Learn all about these changing markets in our latest report.

Revenue, testing volumes, technology, products and channels. They are all looked at in this complete report that provides detailed breakdowns by country and regions. Get on top of the situation quickly with our Market Guides and Situation Analysis.

All report data is available in Excel format on request.

Make projections with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. COVID-19. Strategic Situation Analysis
  • 1.2. COVID-19. Guidance for Executives
  • 1.3. COVID-19. Guidance for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Pandemics?
  • 2.2. The Role of Zoonosis
  • 2.3. Market Definition
    • 2.3.1. Assay Volumes.
    • 2.3.2. PCR
    • 2.3.3. PCR Multiplex
    • 2.3.4. SEQ
    • 2.3.5. Antigen
    • 2.3.6. Antibodies
    • 2.3.7. Instruments
    • 2.3.8. Reagents and Kits
    • 2.3.9. Extract
    • 2.3.10. Collect
    • 2.3.11. Public
    • 2.3.12. Hospital
    • 2.3.13. Clinic
    • 2.3.14. Workplace
    • 2.3.15. DTC/OTC
    • 2.3.16. Wastewater
  • 2.4. Methodology
    • 2.4.1. Authors
    • 2.4.2. Sources
  • 2.5. Historical Perspective on Pandemics
    • 2.5.1. HIV/AIDS PANDEMIC 2005-2012
    • 2.5.2. FLU PANDEMIC 1968
    • 2.5.3. ASIAN FLU 1956-1958
    • 2.5.4. SPANISH FLU 1918
    • 2.5.5. SIXTH CHOLERA PANDEMIC 1910-1911
    • 2.5.6. FLU PANDEMIC 1889-1890
    • 2.5.7. THE BLACK DEATH 1346-1353

3. The Pandemic Overview

  • 3.1. What is a Virus?
    • 3.1.1. Is a Virus Alive?
    • 3.1.2. Viral Structure
    • 3.1.3. The Viral Genome
    • 3.1.4. Viral Mutation
  • 3.2. The Coronavirus
    • 3.2.1. Severe acute respiratory syndrome (SARS)
    • 3.2.2. Middle East respiratory syndrome (MERS)
    • 3.2.3. COVID-19. The SARS CoV 2 Virus
      • 3.2.3.1. Signs and symptoms
      • 3.2.3.2. Transmission
      • 3.2.3.3. Diagnosis
      • 3.2.3.4. Prevention
      • 3.2.3.5. Management
      • 3.2.3.6. Prognosis
      • 3.2.3.7. A Note on Global Statistics Reporting
  • 3.3. Pandemic Diagnostics
    • 3.3.1. Risk Management-Spark and Spread
    • 3.3.2. Dx Technology-Nucleic Acid Based
    • 3.3.3. Dx Technology-Immunoassay
    • 3.3.4. Time to Market and Preparedness Issues

4. Diagnostic Company Profiles

  • 4.1. Abacus Diagnostica
  • 4.2. Abbott Diagnostics
  • 4.3. Accelerate Diagnostics
  • 4.4. Acces Bio
  • 4.5. Advanced Biological Laboratories
  • 4.6. Agena Bioscience, Inc.
  • 4.7. Agilent/Dako
  • 4.8. Altona Diagnostics
  • 4.9. Alveo Technologies
  • 4.10. Anatolia Geneworks
  • 4.11. Applied BioCode
  • 4.12. Applied DNA Sciences
  • 4.13. Assurance Scientific Laboratories
  • 4.14. Aus Diagnostics
  • 4.15. Autobio Diagnostics
  • 4.16. Beckman Coulter Diagnostics
  • 4.17. Becton, Dickinson and Company
  • 4.18. BGI Genomics Co. Ltd
  • 4.19. BillionToOne
  • 4.20. Binx Health
  • 4.21. Biocartis
  • 4.22. Biodesix Inc.
  • 4.23. BioFire Diagnostics (bioMérieux)
  • 4.24. Biolidics Ltd
  • 4.25. bioMérieux Diagnostics
  • 4.26. Bioneer Corporation
  • 4.27. Bio-Rad Laboratories, Inc
  • 4.28. Bio-Reference Laboratories
  • 4.29. Bosch Healthcare Solutions GmbH
  • 4.30. Cepheid (Danaher)
  • 4.31. Chembio
  • 4.32. Co Diagnostics
  • 4.33. Color Genomics
  • 4.34. Cue Health
  • 4.35. Curetis N.V. / Curetis GmbH
  • 4.36. Diagenode Diagnostics
  • 4.37. Diasorin S.p.A.
  • 4.38. Ellume
  • 4.39. Enzo Life Sciences, Inc.
  • 4.40. Everywell
  • 4.41. Fluxergy
  • 4.42. Fulgent Genetics
  • 4.43. Fusion Genomics.
  • 4.44. Genedrive
  • 4.45. Genetic Signatures
  • 4.46. GenMark Dx (Roche)
  • 4.47. Gold Standard Diagnostics
  • 4.48. Hologic
  • 4.49. Illumina
  • 4.50. Immunexpress
  • 4.51. Inflammatix
  • 4.52. Janssen Diagnostics
  • 4.53. Karius
  • 4.54. Laboratory Corporation of America
  • 4.55. Letsgetchecked
  • 4.56. Lexagene
  • 4.57. Luminex Corp
  • 4.58. LumiraDx
  • 4.59. Mammoth Biosciences
  • 4.60. Mayo Clinic Laboratories
  • 4.61. Mbio Diagnostics
  • 4.62. Meridian Bioscience
  • 4.63. Mesa Biotech (Thermo Fisher)
  • 4.64. Mobidiag (Hologic)
  • 4.65. Nanomix
  • 4.66. Novacyt
  • 4.67. Orasure
  • 4.68. Ortho Clinical Diagnostics
  • 4.69. Oxford Nanopore Technologies
  • 4.70. Perkin Elmer
  • 4.71. Primerdesign (Novacyt)
  • 4.72. Prominex
  • 4.73. Qiagen Gmbh
  • 4.74. www.quantumdx.com
  • 4.75. Quest Diagnostics
  • 4.76. Quidel
  • 4.77. Randox Toxicology
  • 4.78. Roche Molecular Diagnostics
  • 4.79. SD Biosensor
  • 4.80. Seegene
  • 4.81. Sherlock Biosciences
  • 4.82. Siemens Healthineers
  • 4.83. Sona Nanotech
  • 4.84. SpeeDx
  • 4.85. Thermo Fisher Scientific Inc
  • 4.86. Veredus Laboratories
  • 4.87. Vircell
  • 4.88. Visby Medical
  • 4.89. YD Diagnostics
  • 4.90. Zhejiang Orient Gene Biotech

5. Covid-19 Diagnostics Recent Developments

  • 5.1. Recent Developments-Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. LetsGetChecked Closes $150M Funding Round
  • 5.3. Novacyt Gets CE Mark for Multigene SARS-CoV-2 Test, Launches RUO Variant Assay
  • 5.4. Abbott Sees Sharp Decline in COVID-19 Test Revenue
  • 5.5. Phosphorus Diagnostics Gets EUA for DTC C19 Test, Sample Collection Kit
  • 5.6. NY Times Explores Multiplex Testing
  • 5.7. Hologic Banking on MDx Acquisitions
  • 5.8. Demand for Cepheid SARS-CoV-2 Point-of-Care Tests to Continue Through 2022
  • 5.9. DiaSorin Acquires Luminex to Broaden MDx Portfolio, Expand US Presence
  • 5.10. LumiraDx to Go Public Through SPAC
  • 5.11. Eurofins Test Helps to ID Mutations
  • 5.12. Roche Sees Growing Opportunities for Diagnostics
  • 5.13. Roche to Acquire GenMark Diagnostics for $1.8B
  • 5.14. Fulgent Genetics s to Use COVID-19 Testing Gains to Grow Clinical Sequencing
  • 5.15. LexaGene Syndromic Panel Platform Lets Labs Customize Targets
  • 5.16. FDA Grants EUAs for DTC Sample Collection Kit, Two Molecular Tests
  • 5.17. At-Home Infectious Disease Test Developer Lucira Health Goes Public

6. The Global Market for COVID-19 Diagnostics

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart-Global Market by Country
    • 6.1.3. Table-Global Market by Country-Assay Volumes
  • 6.2. Global Market by Technology-Overview
    • 6.2.1. Table-Global Market by Technology
    • 6.2.2. Chart-Global Market by Technology-Base/Final Year Comparison
    • 6.2.3. Chart-Global Market by Technology-Base Year
    • 6.2.4. Chart-Global Market by Technology-End Year
    • 6.2.5. Chart-Global Market by Technology-Share by Year
    • 6.2.6. Chart-Global Market by Technology-Segments Growth
  • 6.3. Global Market by Product-Overview
    • 6.3.1. Table-Global Market by Product
    • 6.3.2. Chart-Global Market by Product-Base/Final Year Comparison
    • 6.3.3. Chart-Global Market by Product-Base Year
    • 6.3.4. Chart-Global Market by Product-End Year
    • 6.3.5. Chart-Global Market by Product-Share by Year
    • 6.3.6. Chart-Global Market by Product-Segments Growth
  • 6.4. Global Market by Channel-Overview
    • 6.4.1. Table-Global Market by Channel
    • 6.4.2. Chart-Global Market by Channel-Base/Final Year Comparison
    • 6.4.3. Chart-Global Market by Channel-Base Year
    • 6.4.4. Chart-Global Market by Channel-End Year
    • 6.4.5. Chart-Global Market by Channel-Share by Year
    • 6.4.6. Chart-Global Market by Channel-Segments Growth

7. Global COVID-19 Diagnostic Markets-By Technology

  • 7.1. PCR
    • 7.1.1. Table PCR-by Country
    • 7.1.2. Chart-PCR Growth
  • 7.2. PCR Multiplex
    • 7.2.1. Table PCR Multiplex-by Country
    • 7.2.2. Chart-PCR Multiplex Growth
  • 7.3. Sequencing
    • 7.3.1. Table Sequencing-by Country
    • 7.3.2. Chart-Sequencing Growth
  • 7.4. Antibody
    • 7.4.1. Table Antibody-by Country
    • 7.4.2. Chart-Antibody Growth
  • 7.5. Antigen
    • 7.5.1. Table Antigen-by Country
    • 7.5.2. Chart-Antigen Growth

8. Global COVID-19 Diagnostic Markets-By Product

  • 8.1. Instruments
    • 8.1.1. Table Instruments-by Country
    • 8.1.2. Chart-Instruments Growth
  • 8.2. Reagents & Kits
    • 8.2.1. Table Reagents & Kits-by Country
    • 8.2.2. Chart-Reagents & Kits Growth
  • 8.3. Extraction
    • 8.3.1. Table Extraction-by Country
    • 8.3.2. Chart-Extraction Growth
  • 8.4. Collection
    • 8.4.1. Table Collection-by Country
    • 8.4.2. Chart-Collection Growth

9. Global COVID-19 Diagnostic Markets-By Channel

  • 9.1. Public
    • 9.1.1. Table Public-by Country
    • 9.1.2. Chart-Public Growth
  • 9.2. Hospital
    • 9.2.1. Table Hospital-by Country
    • 9.2.2. Chart-Hospital Growth
  • 9.3. Clinic
    • 9.3.1. Table Clinic-by Country
    • 9.3.2. Chart-Clinic Growth
  • 9.4. Workplace
    • 9.4.1. Table Workplace-by Country
    • 9.4.2. Chart-Workplace Growth
  • 9.5. DTC/OTC
    • 9.5.1. Table DTC/OTC-by Country
    • 9.5.2. Chart-DTC/OTC Growth
  • 9.6. Wastewater
    • 9.6.1. Table Wastewater-by Country
    • 9.6.2. Chart-Wastewater Growth

10. Appendix

  • 10.1. U.S., Europe, Asia Approved COVID-19 Assays

Table of Tables

  • Table 1: Who List of Potential Pandemic Pathogens
  • Table 2: Characteristics of Coronavirus Pandemic Infections
  • Table 3: COVID-19 Symptoms
  • Table 4: Global Market by Region
  • Table 5: Global Market Assay Volumes by Region
  • Table 6: Global Market by Technology
  • Table 7: Global Market by Product
  • Table 8: Global Market by Channel
  • Table 9: PCR by Country
  • Table 10: PCR Multiplex by Country
  • Table 11: Sequencing by Country
  • Table 12: Antibody by Country
  • Table 13: Antigen by Country
  • Table 14: Instruments by Country
  • Table 15: Reagents & Kits by Country
  • Table 16: Extraction by Country
  • Table 17: Collection by Country
  • Table 18: Public by Country
  • Table 19: Hospital by Country
  • Table 20: Clinic by Country
  • Table 21: Workplace by Country
  • Table 22: DTC/OTC by Country
  • Table 23: Wastewater by Country
  • Table 24: Approved Covid-19 Assays

Table of Figures

  • Figure 1: Testing Volumes To Date for Select Countries
  • Figure 2: Global Distribution Pandemic Preparedness
  • Figure 3: Global Pandemic Pathogen Status
  • Figure 4: Estimated Economic Impact of Viral Pandemic by Region
  • Figure 5: Historical Pandemics Infographic
  • Figure 6: Antigenic Drift Creates a new Strain of Virus
  • Figure 7: Structure of Coronaviruses
  • Figure 8: Global Market Share Chart
  • Figure 9: Base/Final Year Comparison Chart
  • Figure 10: Global Markets by Technology Base Year
  • Figure 11: Global Markets by Technology End Year
  • Figure 12: Global Markets by Technology Share by Year
  • Figure 13: Global Markets by Technology Segment Growth
  • Figure 14: Global Market by Product Base vs. Final
  • Figure 15: Global Market by Product Base Year
  • Figure 16: Global Market by Product End Year
  • Figure 17: Global Market by Product Share by Year
  • Figure 18: Global Market by Product Segments Growth
  • Figure 19: global Market by Channel - Base vs. Final
  • Figure 20: global Market by Channel - Base Year
  • Figure 21: global Market by Channel - End Year
  • Figure 22: global Market by Channel - Share by Year
  • Figure 23: global Market by Channel - Segments Growth
  • Figure 24: PCR Growth
  • Figure 25: PCR Multiplex Growth
  • Figure 26: Sequencing Growth
  • Figure 27: Antibody Growth
  • Figure 28: Antigen Growth
  • Figure 29: Instruments Growth
  • Figure 30: Reagents & Kits Growth
  • Figure 31: Extraction Growth
  • Figure 32: Collection Growth
  • Figure 33: Public Growth
  • Figure 34: Hospital Growth
  • Figure 35: Clinic Growth
  • Figure 36: Workplace Growth
  • Figure 37: DTC/OTC Growth
  • Figure 38: Wastewater Growth